Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omiganan in papulopustular rosacea
NCT02547441Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Dec 2015
- Primary completion
- Jul 2017
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of CLS001 topical gel vehicle in papulopustular rosacea (2 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Change in Inflammatory Lesion Count From Baseline at 12 weeks and Percentage of Participants Who Achieved 2 Grade IGA Reduction at 12 weeks. Started Dec 2015; status: completed.
02
Drugs
CLS001 topical gel vehicle
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT02547441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547441.